Medical Technology, Healthcare Technology, Laboratory Testing, Disease Prevention & Treatment

Location: Knoxville, TN

CEO: Eric Mayer

New Day Diagnostics is a commercial-stage diagnostics company offering the first FDA-approved blood-based test for colorectal cancer, ColoHealth, which addresses low screening compliance with a non-invasive, accessible alternative to colonoscopies and stool-based tests.  

Backed by a strong leadership team and scientific expertise, the company is developing an expanded pipeline—including the reimbursable ColoPlexPLUS—for early detection of cancer and precancerous polyps. It also provides rapid tests for digestive diseases and operates a revenue-generating bioresearch division offering clinical trial and assay development services.  

With a vertically integrated model, New Day develops, validates, and commercializes diagnostics through direct-to-consumer, clinical, and distribution channels. Its target markets include primary care providers, telehealth platforms, large health systems, and biopharma clients.  

Interested in Investing?

Community Equity Partners works with accredited investors. We structure our investments through Special Purpose Vehicles (SPVs) for each company, prepare diligence reports and communicate company updates with our investor-members.

Please fill out the form to indicate your interest in investing in this company.

GET IN ON THIS DEAL
Select all that apply.
Thank you for subscribing!